"Neoplasm Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
| Descriptor ID |
D009363
|
| MeSH Number(s) |
D12.776.624
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Proteins".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Proteins".
This graph shows the total number of publications written about "Neoplasm Proteins" by people in this website by year, and whether "Neoplasm Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 |
| 1996 | 9 | 3 | 12 |
| 1997 | 1 | 3 | 4 |
| 1998 | 5 | 3 | 8 |
| 1999 | 7 | 1 | 8 |
| 2000 | 8 | 6 | 14 |
| 2001 | 11 | 1 | 12 |
| 2002 | 8 | 7 | 15 |
| 2003 | 9 | 6 | 15 |
| 2004 | 12 | 8 | 20 |
| 2005 | 5 | 12 | 17 |
| 2006 | 14 | 4 | 18 |
| 2007 | 11 | 12 | 23 |
| 2008 | 7 | 11 | 18 |
| 2009 | 10 | 6 | 16 |
| 2010 | 7 | 5 | 12 |
| 2011 | 13 | 7 | 20 |
| 2012 | 9 | 7 | 16 |
| 2013 | 10 | 3 | 13 |
| 2014 | 12 | 9 | 21 |
| 2015 | 16 | 8 | 24 |
| 2016 | 8 | 4 | 12 |
| 2017 | 13 | 7 | 20 |
| 2018 | 19 | 8 | 27 |
| 2019 | 15 | 6 | 21 |
| 2020 | 9 | 2 | 11 |
| 2021 | 11 | 5 | 16 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 3 | 4 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Proteins" by people in Profiles.
-
MAGE-A4 induces non-small cell lung cancer and tumor-promoting plasma cell accumulation. Sci Adv. 2025 Feb 14; 11(7):eads4227.
-
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 Dec 30; 15(1):10743.
-
Distinct landscape and clinical implications of therapy-related clonal hematopoiesis. J Clin Invest. 2024 Oct 01; 134(19).
-
Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. J Clin Invest. 2024 Oct 01; 134(22).
-
Perturbing TET2 condensation promotes aberrant genome-wide DNA methylation and curtails leukaemia cell growth. Nat Cell Biol. 2024 Dec; 26(12):2154-2167.
-
The cancer-associated secretory phenotype: a new frontier in targeted therapeutics. J Clin Invest. 2024 Sep 03; 134(17).
-
Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma. J Clin Invest. 2024 Aug 13; 134(19).
-
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J Immunother Cancer. 2024 Jul 22; 12(7).
-
Brd4::Nutm1 fusion gene initiates NUT carcinoma in vivo. Life Sci Alliance. 2024 Jul; 7(7).
-
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application. Haematologica. 2024 05 01; 109(5):1348-1358.